Top of the morning to you. Another busy day is unfolding here on the Pharmalot campus, where we are mulling over our cluttered calendar and plotting our next moves. No doubt, you can relate. After all, this is only the middle of the week and there is so much to be done. This calls, as you may imagine, for a hot cup of stimulation. So we are quaffing cinnamon hazelnut for now. Feel free to join us. Meanwhile, here are some tidbits. The world is a busy place, yes? Hope you make your way today. …
Moderna (MRNA) will ask the U.S. Food and Drug Administration to authorize its Covid-19 vaccine for emergency use in children aged 6 months to 6 years, a group for which there are currently no authorized Covid shots, STAT informs us. The announcement came as the company released interim data from two clinical trials of its vaccine in children under 6 years of age. Moderna said the studies — in children aged 6 months to 23 months, and 2 to 6 years — showed the vaccine generated similar immune responses as those seen in adults aged 18 to 25 who received two doses of its adult Covid vaccine.
Create a display name to comment
This name will appear with your comment